Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Summary

The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.

Conditions

• Pancreatic Cancer
• Pancreas Cancer
• Pancreatic Adenocarcinoma Resectable
• Pancreatic Ductal Adenocarcinoma
• Pancreas Metastases

Interventions

DRUG

Ascorbic Acid

combination therapy

DRUG

Paclitaxel protein-bound

combination therapy

DRUG

Cisplatin

combination therapy

DRUG

Gemcitabine

combination therapy

Sponsors & Collaborators

• Stand Up To Cancer

  collaborator OTHER

• Cancer Research UK

  collaborator OTHER

• Lustgarten Foundation

  collaborator OTHER

• Translational Genomics Research Institute

  collaborator OTHER

• Princeton University

  collaborator OTHER

• Salk Institute for Biological Studies

  collaborator OTHER

• Cold Spring Harbor Laboratory

  collaborator OTHER

• Barts Cancer Institute

  collaborator OTHER

• University of Arizona

  collaborator OTHER

• Imaging Endpoints

  collaborator UNKNOWN

• HonorHealth Research Institute

  lead OTHER

Principal Investigators

• Gayle S Jameson, RN, MSN, ACNP-BC, AOCN · HonorHealth Research Institute

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-12-15

Primary Completion

2021-09-14

Completion

2022-01-10

FDA Drug

Yes

Countries

• United States

Study Locations